These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 33920790)
21. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study. Parit R; Jayavel S Eur J Pharmacol; 2021 Apr; 896():173899. PubMed ID: 33508281 [TBL] [Abstract][Full Text] [Related]
22. An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine. Davoudi F; Miyashita S; Yoo TK; Lee PT; Foster GP Crit Pathw Cardiol; 2022 Sep; 21(3):123-129. PubMed ID: 35994720 [TBL] [Abstract][Full Text] [Related]
23. COVID-19 and cardiovascular disease: characteristic features in older patients. Boureau AS; de Decker L; Berrut G; Hanon O Geriatr Psychol Neuropsychiatr Vieil; 2020 Jun; 18(2):141-148. PubMed ID: 33064080 [TBL] [Abstract][Full Text] [Related]
24. Bone biology and COVID-19 infection: Is ACE2 a potential influence factor? Tao H; Bai J; Zhang W; Zheng K; Guan P; Ge G; Li M; Geng D Med Hypotheses; 2020 Nov; 144():110178. PubMed ID: 33254500 [TBL] [Abstract][Full Text] [Related]
25. The Science Underlying COVID-19: Implications for the Cardiovascular System. Liu PP; Blet A; Smyth D; Li H Circulation; 2020 Jul; 142(1):68-78. PubMed ID: 32293910 [TBL] [Abstract][Full Text] [Related]
26. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2. Buckley LF; Cheng JWM; Desai A J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766 [TBL] [Abstract][Full Text] [Related]
28. A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice. Wang Y; Takeshita H; Yamamoto K; Huang Y; Wang C; Nakajima T; Nozato Y; Fujimoto T; Yokoyama S; Hongyo K; Nakagami F; Akasaka H; Takami Y; Takeya Y; Sugimoto K; Rakugi H FASEB J; 2021 Mar; 35(3):e21419. PubMed ID: 33566370 [TBL] [Abstract][Full Text] [Related]
29. Vascular Dysfunction and Its Cardiovascular Consequences During and After COVID-19 Infection: A Narrative Review. Kar M Vasc Health Risk Manag; 2022; 18():105-112. PubMed ID: 35283631 [TBL] [Abstract][Full Text] [Related]
30. Potential effects of COVID-19 on reproductive systems and fertility; assisted reproductive technology guidelines and considerations: a review. Lee WY; Mok A; Chung JPW Hong Kong Med J; 2021 Apr; 27(2):118-126. PubMed ID: 33853972 [TBL] [Abstract][Full Text] [Related]
31. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality. Stafford EG; Riviere JE; Xu X; Kawakami J; Wyckoff GJ; Jaberi-Douraki M J Am Pharm Assoc (2003); 2020; 60(6):e145-e152. PubMed ID: 32561317 [TBL] [Abstract][Full Text] [Related]
32. The Potential Mechanisms Behind Adverse Effect of Coronavirus Disease-19 on Heart and Liver Damage: A Review. Daba TM; Mokonon M; Niguse E; Getahun M Ethiop J Health Sci; 2024 Jan; 34(1):85-100. PubMed ID: 38957334 [TBL] [Abstract][Full Text] [Related]
33. Pathogenesis and management of myocardial injury in coronavirus disease 2019. Wei ZY; Geng YJ; Huang J; Qian HY Eur J Heart Fail; 2020 Nov; 22(11):1994-2006. PubMed ID: 32683753 [TBL] [Abstract][Full Text] [Related]
34. Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19. Medzikovic L; Cunningham CM; Li M; Amjedi M; Hong J; Ruffenach G; Eghbali M J Mol Cell Cardiol; 2020 Nov; 148():25-33. PubMed ID: 32835666 [TBL] [Abstract][Full Text] [Related]
35. Cardiac Complications of COVID-19 Infection and the Role of Physical Activity. Smer A; Squires RW; Bonikowske AR; Allison TG; Mainville RN; Williams MA J Cardiopulm Rehabil Prev; 2023 Jan; 43(1):8-14. PubMed ID: 35839441 [TBL] [Abstract][Full Text] [Related]
36. COVID-19 and cardiovascular disease in patients with chronic kidney disease. Del Vecchio L; Balafa O; Dounousi E; Ekart R; Fernandez BF; Mark PB; Sarafidis P; Valdivielso JM; Ferro CJ; Mallamaci F Nephrol Dial Transplant; 2024 Jan; 39(2):177-189. PubMed ID: 37771078 [TBL] [Abstract][Full Text] [Related]
37. Consequences of COVID-19 for the Pancreas. Abramczyk U; Nowaczyński M; Słomczyński A; Wojnicz P; Zatyka P; Kuzan A Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055050 [TBL] [Abstract][Full Text] [Related]
38. The mechanism of multiple organ dysfunction syndrome in patients with COVID-19. Zhao W; Li H; Li J; Xu B; Xu J J Med Virol; 2022 May; 94(5):1886-1892. PubMed ID: 35088424 [TBL] [Abstract][Full Text] [Related]
39. Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19. Hamouche W; Bisserier M; Brojakowska A; Eskandari A; Fish K; Goukassian DA; Hadri L J Mol Cell Cardiol; 2021 Apr; 153():72-85. PubMed ID: 33373644 [TBL] [Abstract][Full Text] [Related]
40. Cardiovascular Manifestations of Long COVID: A Review. Krug E; Geckeler KC; Frishman WH Cardiol Rev; 2024 Sep-Oct 01; 32(5):402-407. PubMed ID: 36728728 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]